A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Identifieur interne : 004859 ( Main/Exploration ); précédent : 004858; suivant : 004860A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Auteurs : Gerd R. Burmester [Allemagne] ; Andrea Rubbert-Roth [Allemagne] ; Alain Cantagrel [France] ; Stephen Hall [Australie] ; Piotr Leszczynski [Pologne] ; Daniel Feldman [Brésil] ; Madura J. Rangaraj [États-Unis] ; Georgia Roane [États-Unis] ; Charles Ludivico [États-Unis] ; Peng Lu [États-Unis] ; Lucy Rowell [Royaume-Uni] ; Min Bao [États-Unis] ; Eduardo F. Mysler [Argentine]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013.
Abstract
This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARD).
Patients (n=1262) were randomly assigned to receive tocilizumab-SC 162 mg weekly+placebo-IV every 4 weeks or tocilizumab-IV 8 mg/kg every 4 weeks+placebo-SC weekly in combination with traditional DMARD. The primary outcome was to demonstrate the non-inferiority of tocilizumab-SC to tocilizumab-IV with regard to the proportion of patients in each group achieving an American College of Rheumatology (ACR) 20 response at week 24 using a 12% non-inferiority margin (NIM). Secondary outcomes were disease activity score using 28 joints (DAS28), ACR responses, health assessment questionnaire scores and safety assessments.
At week 24, 69.4% (95% CI 65.5 to 73.2) of tocilizumab-SC-treated patients versus 73.4% (95% CI 69.6 to 77.1) of tocilizumab-IV-treated patients achieved an ACR20 response (weighted difference between groups −4.0%, 95% CI −9.2 to 1.2); the 12% NIM was met. ACR50/70 responses, DAS28 and physical function improvements were comparable between the tocilizumab-SC and tocilizumab-IV groups. The safety profiles of tocilizumab-SC and tocilizumab-IV were similar, and the most common adverse event was infection. Injection-site reactions (ISR) occurred more frequently in the tocilizumab-SC group than in the tocilizumab-IV (placebo-SC) group. No anaphylaxis was reported over the 24 weeks.
Tocilizumab-SC 162 mg weekly demonstrated comparable efficacy to tocilizumab-IV 8 mg/kg. The safety profile of tocilizumab-SC is consistent with the known and well-established safety profile of tocilizumab-IV, with the exception of a higher incidence of ISR, which were more common with tocilizumab-SC administration.
Url:
DOI: 10.1136/annrheumdis-2013-203523
PubMed: 23904473
PubMed Central: 3888614
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002255
- to stream Pmc, to step Curation: 002105
- to stream Pmc, to step Checkpoint: 001C79
- to stream Ncbi, to step Merge: 001388
- to stream Ncbi, to step Curation: 001388
- to stream Ncbi, to step Checkpoint: 001388
- to stream Main, to step Merge: 004982
- to stream Main, to step Curation: 004859
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin</institution>,<addr-line>Berlin</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Klinikum der Universität zu Köln</institution>,<addr-line>Koln</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Centre Hospitalier Universitaire de Toulouse</institution>,<addr-line>Toulouse</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:aff id="af4"><institution>Cabrini Medical Centre</institution>,<addr-line>Malvern</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name><affiliation wicri:level="1"><nlm:aff id="af5"><institution>J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences</institution>,<country>Poland</country></nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name><affiliation wicri:level="1"><nlm:aff id="af6"><institution>Universidade Federal de São Paulo</institution>,<addr-line>São Paulo</addr-line>,<country>Brazil</country></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Arthritis & Diabetes Clinic, Inc</institution>,<addr-line>Monroe, Louisiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name><affiliation wicri:level="1"><nlm:aff id="af8"><institution>Rheumatology Associates, P.A.</institution>,<addr-line>Charleston, South Carolina</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><affiliation wicri:level="1"><nlm:aff id="af9"><institution>East Penn Rheumatology Associates, PC</institution>,<addr-line>Bethlehem, Pennsylvania</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Peng" sort="Lu, Peng" uniqKey="Lu P" first="Peng" last="Lu">Peng Lu</name><affiliation wicri:level="1"><nlm:aff id="af10"><institution>Hoffmann-La Roche Inc</institution>,<addr-line>Nutley, New Jersey</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name><affiliation wicri:level="1"><nlm:aff id="af11"><institution>Roche Products Limited</institution>,<addr-line>Welwyn Garden City</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="1"><nlm:aff id="af12"><institution>Genentech, Inc</institution>,<addr-line>South San Francisco, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name><affiliation wicri:level="1"><nlm:aff id="af13"><institution>Organizacion Medica de Investigación</institution>,<addr-line>Buenos Aires</addr-line>,<country>Argentina</country></nlm:aff><country xml:lang="fr">Argentine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23904473</idno><idno type="pmc">3888614</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888614</idno><idno type="RBID">PMC:3888614</idno><idno type="doi">10.1136/annrheumdis-2013-203523</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">002255</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002255</idno><idno type="wicri:Area/Pmc/Curation">002105</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002105</idno><idno type="wicri:Area/Pmc/Checkpoint">001C79</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001C79</idno><idno type="wicri:Area/Ncbi/Merge">001388</idno><idno type="wicri:Area/Ncbi/Curation">001388</idno><idno type="wicri:Area/Ncbi/Checkpoint">001388</idno><idno type="wicri:doubleKey">0003-4967:2013:Burmester G:a:randomised:double</idno><idno type="wicri:Area/Main/Merge">004982</idno><idno type="wicri:Area/Main/Curation">004859</idno><idno type="wicri:Area/Main/Exploration">004859</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)</title><author><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name><affiliation wicri:level="1"><nlm:aff id="af1"><institution>Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin</institution>,<addr-line>Berlin</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Klinikum der Universität zu Köln</institution>,<addr-line>Koln</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Centre Hospitalier Universitaire de Toulouse</institution>,<addr-line>Toulouse</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name><affiliation wicri:level="1"><nlm:aff id="af4"><institution>Cabrini Medical Centre</institution>,<addr-line>Malvern</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name><affiliation wicri:level="1"><nlm:aff id="af5"><institution>J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences</institution>,<country>Poland</country></nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name><affiliation wicri:level="1"><nlm:aff id="af6"><institution>Universidade Federal de São Paulo</institution>,<addr-line>São Paulo</addr-line>,<country>Brazil</country></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name><affiliation wicri:level="1"><nlm:aff id="af7"><institution>Arthritis & Diabetes Clinic, Inc</institution>,<addr-line>Monroe, Louisiana</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name><affiliation wicri:level="1"><nlm:aff id="af8"><institution>Rheumatology Associates, P.A.</institution>,<addr-line>Charleston, South Carolina</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><affiliation wicri:level="1"><nlm:aff id="af9"><institution>East Penn Rheumatology Associates, PC</institution>,<addr-line>Bethlehem, Pennsylvania</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Peng" sort="Lu, Peng" uniqKey="Lu P" first="Peng" last="Lu">Peng Lu</name><affiliation wicri:level="1"><nlm:aff id="af10"><institution>Hoffmann-La Roche Inc</institution>,<addr-line>Nutley, New Jersey</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name><affiliation wicri:level="1"><nlm:aff id="af11"><institution>Roche Products Limited</institution>,<addr-line>Welwyn Garden City</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><affiliation wicri:level="1"><nlm:aff id="af12"><institution>Genentech, Inc</institution>,<addr-line>South San Francisco, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name><affiliation wicri:level="1"><nlm:aff id="af13"><institution>Organizacion Medica de Investigación</institution>,<addr-line>Buenos Aires</addr-line>,<country>Argentina</country></nlm:aff><country xml:lang="fr">Argentine</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of the Rheumatic Diseases</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objectives</title><p>This study compared the efficacy and safety of subcutaneous (SC) versus intravenous (IV) formulations of tocilizumab in patients with rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs (DMARD).</p></sec><sec><title>Methods</title><p>Patients (n=1262) were randomly assigned to receive tocilizumab-SC 162 mg weekly+placebo-IV every 4 weeks or tocilizumab-IV 8 mg/kg every 4 weeks+placebo-SC weekly in combination with traditional DMARD. The primary outcome was to demonstrate the non-inferiority of tocilizumab-SC to tocilizumab-IV with regard to the proportion of patients in each group achieving an American College of Rheumatology (ACR) 20 response at week 24 using a 12% non-inferiority margin (NIM). Secondary outcomes were disease activity score using 28 joints (DAS28), ACR responses, health assessment questionnaire scores and safety assessments.</p></sec><sec><title>Results</title><p>At week 24, 69.4% (95% CI 65.5 to 73.2) of tocilizumab-SC-treated patients versus 73.4% (95% CI 69.6 to 77.1) of tocilizumab-IV-treated patients achieved an ACR20 response (weighted difference between groups −4.0%, 95% CI −9.2 to 1.2); the 12% NIM was met. ACR50/70 responses, DAS28 and physical function improvements were comparable between the tocilizumab-SC and tocilizumab-IV groups. The safety profiles of tocilizumab-SC and tocilizumab-IV were similar, and the most common adverse event was infection. Injection-site reactions (ISR) occurred more frequently in the tocilizumab-SC group than in the tocilizumab-IV (placebo-SC) group. No anaphylaxis was reported over the 24 weeks.</p></sec><sec><title>Conclusions</title><p>Tocilizumab-SC 162 mg weekly demonstrated comparable efficacy to tocilizumab-IV 8 mg/kg. The safety profile of tocilizumab-SC is consistent with the known and well-established safety profile of tocilizumab-IV, with the exception of a higher incidence of ISR, which were more common with tocilizumab-SC administration.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Scott, Dl" uniqKey="Scott D">DL Scott</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maini, Rn" uniqKey="Maini R">RN Maini</name></author><author><name sortKey="Taylor, Pc" uniqKey="Taylor P">PC Taylor</name></author><author><name sortKey="Szechinski, J" uniqKey="Szechinski J">J Szechinski</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohta, S" uniqKey="Ohta S">S Ohta</name></author><author><name sortKey="Tsuru, T" uniqKey="Tsuru T">T Tsuru</name></author><author><name sortKey="Terao, K" uniqKey="Terao K">K Terao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stubenrauch, K" uniqKey="Stubenrauch K">K Stubenrauch</name></author><author><name sortKey="Wessels, U" uniqKey="Wessels U">U Wessels</name></author><author><name sortKey="Birnboeck, H" uniqKey="Birnboeck H">H Birnboeck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Beaulieu, A" uniqKey="Beaulieu A">A Beaulieu</name></author><author><name sortKey="Rubbert Roth, A" uniqKey="Rubbert Roth A">A Rubbert-Roth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Mckay, Jd" uniqKey="Mckay J">JD McKay</name></author><author><name sortKey="Nasonov, El" uniqKey="Nasonov E">EL Nasonov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kremer, Jm" uniqKey="Kremer J">JM Kremer</name></author><author><name sortKey="Blanco, R" uniqKey="Blanco R">R Blanco</name></author><author><name sortKey="Brzosko, M" uniqKey="Brzosko M">M Brzosko</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author><author><name sortKey="Keystone, E" uniqKey="Keystone E">E Keystone</name></author><author><name sortKey="Tony, Hp" uniqKey="Tony H">HP Tony</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keystone, Ec" uniqKey="Keystone E">EC Keystone</name></author><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Klareskog, L" uniqKey="Klareskog L">L Klareskog</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van De Putte, Lb" uniqKey="Van De Putte L">LB van de Putte</name></author><author><name sortKey="Atkins, C" uniqKey="Atkins C">C Atkins</name></author><author><name sortKey="Malaise, M" uniqKey="Malaise M">M Malaise</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Australie</li><li>Brésil</li><li>France</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Burmester, Gerd R" sort="Burmester, Gerd R" uniqKey="Burmester G" first="Gerd R" last="Burmester">Gerd R. Burmester</name></noRegion><name sortKey="Rubbert Roth, Andrea" sort="Rubbert Roth, Andrea" uniqKey="Rubbert Roth A" first="Andrea" last="Rubbert-Roth">Andrea Rubbert-Roth</name></country><country name="France"><noRegion><name sortKey="Cantagrel, Alain" sort="Cantagrel, Alain" uniqKey="Cantagrel A" first="Alain" last="Cantagrel">Alain Cantagrel</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Hall, Stephen" sort="Hall, Stephen" uniqKey="Hall S" first="Stephen" last="Hall">Stephen Hall</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Leszczynski, Piotr" sort="Leszczynski, Piotr" uniqKey="Leszczynski P" first="Piotr" last="Leszczynski">Piotr Leszczynski</name></noRegion></country><country name="Brésil"><noRegion><name sortKey="Feldman, Daniel" sort="Feldman, Daniel" uniqKey="Feldman D" first="Daniel" last="Feldman">Daniel Feldman</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Rangaraj, Madura J" sort="Rangaraj, Madura J" uniqKey="Rangaraj M" first="Madura J" last="Rangaraj">Madura J. Rangaraj</name></noRegion><name sortKey="Bao, Min" sort="Bao, Min" uniqKey="Bao M" first="Min" last="Bao">Min Bao</name><name sortKey="Lu, Peng" sort="Lu, Peng" uniqKey="Lu P" first="Peng" last="Lu">Peng Lu</name><name sortKey="Ludivico, Charles" sort="Ludivico, Charles" uniqKey="Ludivico C" first="Charles" last="Ludivico">Charles Ludivico</name><name sortKey="Roane, Georgia" sort="Roane, Georgia" uniqKey="Roane G" first="Georgia" last="Roane">Georgia Roane</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Rowell, Lucy" sort="Rowell, Lucy" uniqKey="Rowell L" first="Lucy" last="Rowell">Lucy Rowell</name></noRegion></country><country name="Argentine"><noRegion><name sortKey="Mysler, Eduardo F" sort="Mysler, Eduardo F" uniqKey="Mysler E" first="Eduardo F" last="Mysler">Eduardo F. Mysler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004859 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004859 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:3888614
|texte= A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23904473" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |